Jeffers Ann, Owens Shuzi, Koenig Kathleen, Quaid Brandon, Pendurthi Usha R, Rao Vijaya M, Idell Steven, Tucker Torry A
1 Texas Lung Injury Institute and.
Am J Respir Cell Mol Biol. 2015 Jun;52(6):674-82. doi: 10.1165/rcmb.2014-0084OC.
Tissue factor pathway inhibitor (TFPI) is the primary inhibitor of the extrinsic coagulation cascade, and its expression is reported to be relatively stable. Various pathophysiologic agents have been shown to influence TFPI activity by regulating its expression or by modifying the protein. It is not clear how TFPI activity is regulated in normal physiology or in injury. Because thrombin and TFPI are locally elaborated in pleural injury, we sought to determine if thrombin could regulate TFPI in human pleural mesothelial cells (HPMCs). Thrombin significantly decreased TFPI mRNA and protein levels by > 70%. Thrombin-mediated down-regulation of TFPI promoted factor X activation by HPMCs. The ability of thrombin to significantly decrease TFPI mRNA and protein levels was maintained at nanomolar concentrations. Protease-activated receptor (PAR)-1, a mediator of thrombin signaling, is detectable in the mesothelium in human and murine pleural injury. PAR-1 silencing blocked thrombin-mediated decrements of TFPI in HPMCs. Thrombin activates PI3K/Akt and nuclear factor κB (NF-κB) signaling in HPMCs. Inhibition of PI3K (by PX-866) and NF-κB (by SN50) prevented thrombin-mediated TFPI mRNA and protein down-regulation. These are the first studies to demonstrate that thrombin decreases TFPI expression in HPMCs. Our findings demonstrate a novel mechanism by which thrombin regulates TFPI expression in HPMCs and promotes an unrestricted procoagulant response, and suggest that interactions between PI3K and NF-κB signaling pathways are linked in HPMCs and control TFPI expression. These findings raise the possibility that targeting this pathway could limit the ability of the mesothelium to support extravascular fibrin deposition and organization associated with pleural injury.
组织因子途径抑制剂(TFPI)是外源性凝血级联反应的主要抑制剂,据报道其表达相对稳定。各种病理生理因子已被证明可通过调节其表达或修饰蛋白质来影响TFPI活性。目前尚不清楚TFPI活性在正常生理状态或损伤状态下是如何被调节的。由于凝血酶和TFPI在胸膜损伤局部产生,我们试图确定凝血酶是否能调节人胸膜间皮细胞(HPMC)中的TFPI。凝血酶使TFPI mRNA和蛋白水平显著降低>70%。凝血酶介导的TFPI下调促进了HPMC对因子X的激活。凝血酶在纳摩尔浓度下仍能显著降低TFPI mRNA和蛋白水平。蛋白酶激活受体(PAR)-1是凝血酶信号传导的介质,在人和小鼠胸膜损伤的间皮中可检测到。PAR-1沉默可阻断凝血酶介导的HPMC中TFPI的减少。凝血酶激活HPMC中的PI3K/Akt和核因子κB(NF-κB)信号通路。抑制PI3K(通过PX-866)和NF-κB(通过SN50)可防止凝血酶介导的TFPI mRNA和蛋白下调。这些是首次证明凝血酶可降低HPMC中TFPI表达的研究。我们的研究结果证明了一种新的机制,即凝血酶调节HPMC中TFPI的表达并促进不受限制的促凝反应,并表明PI3K和NF-κB信号通路之间的相互作用在HPMC中相互关联并控制TFPI的表达。这些发现增加了这样一种可能性,即靶向该途径可能会限制间皮支持与胸膜损伤相关的血管外纤维蛋白沉积和组织化的能力。